|
|
|
|
|
<br>Modafinil, a wakefulness-selling agent, has gained vital attention since its approval by the U.S. Meals and Drug Administration (FDA) in 1998 for the remedy of narcolepsy, a disorder characterized by extreme daytime sleepiness. Over the years, its off-label uses have expanded, attracting people looking for cognitive enhancement, increased productiveness, and improved focus. This text explores the pharmacological profile of modafinil, its therapeutic functions, potential unintended effects, and important considerations when buying the medicine. |